🔴 NTHI is trading 5.9% down today on profit-taking after UAE regulatory approval spike

NTHI is trading 5.9% down today at $4.81 as investors take profits following a sharp rally driven by regulatory milestones in the UAE.

• The stock recently spiked after Abu Dhabi’s health authority granted IND approval for lead asset NEO100 in multiple adult and pediatric glioma protocols.
• Today's decline is attributed to profit-taking and inherent volatility in the micro-cap biotech sector following the catalyst-driven jump on June 23, 2026.
• The regulatory milestone significantly expands the clinical footprint for NEO100, though the stock remains subject to thin trading volumes.